TT 223 + Glucagon-like peptide-1 analogue
Alternative Names: G1 + GLP-1; TT-223 + GLP-1; TT-223 + LY2428757Latest Information Update: 13 Sep 2024
At a glance
- Originator Transition Therapeutics
- Developer Eli Lilly; Transition Therapeutics
- Class Antihyperglycaemics; Gastrointestinal hormones; Glucagon-like peptides; Neuropeptides; Peptide hormones
- Mechanism of Action Gastrin stimulants; Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus